Related Experiment Video
Updated: Apr 28, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Recent advances in head and neck squamous cell carcinoma--a review
Yaghoub Safdari1, Masoumeh Khalili2, Safar Farajnia3
1Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Faculty of Advanced Medical Science Technologies, Golestan University of Medical Sciences, Gorgan, Iran.
Abstract:
The current review presents the results of the most recent studies performed on different aspects of human head and neck squamous cell carcinoma, including radiosensitivity induction, efficiency improvement of monoclonal antibodies using low-intensity ultrasound, chemical compounds such as toll-like receptor (TLC) agonists, dasatinib, resveratrol and niclosamide, nuclear inhibition of cancer using STAT3 decoy oligonucleotide, efficiency of anti-EGFR monoclonal antibodies in detection of head and neck cancers and other related issues.
Insights
This review explores recent advancements in head and neck squamous cell carcinoma treatment. It covers radiosensitivity, antibody therapies, novel chemical compounds, and nuclear cancer inhibition strategies for improved outcomes.
Area of Science:
- Oncology
- Biotechnology
- Radiotherapy
Background:
- Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge.
- Current treatment modalities require continuous innovation for improved patient survival and quality of life.
Purpose of the Study:
- To review and synthesize recent research findings on novel therapeutic strategies for HNSCC.
- To explore the potential of combining different treatment modalities for enhanced efficacy.
Main Methods:
- Review of recent preclinical and clinical studies on HNSCC.
- Analysis of data on radiosensitivity, targeted therapies, and novel chemical agents.
- Evaluation of nuclear inhibition techniques and antibody-based detection methods.
Main Results:
- Low-intensity ultrasound enhances monoclonal antibody efficiency in HNSCC.
- Specific chemical compounds (Toll-like receptor agonists, dasatinib, resveratrol, niclosamide) show promise.
- STAT3 decoy oligonucleotides offer a novel approach to nuclear cancer inhibition.
- Anti-EGFR monoclonal antibodies demonstrate efficiency in HNSCC detection.
Conclusions:
- Emerging therapeutic strategies, including combination therapies, show significant potential for HNSCC treatment.
- Further research is warranted to translate these findings into clinical practice for improved HNSCC management.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:44Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
Published on: April 3, 2026